Stocks
Replimune Group, Inc.REPL
NASDAQHealthcareBiotechnology$11.99
Price as of · delayed, not real-time
A clinical-stage biotechnology company developing oncolytic immunotherapies, primarily its lead candidate RP1, for solid tumors. It is tracked by investors for its differentiated approach to cancer treatment and upcoming clinical data readouts.
52W Range: $1.50-$16.33
Congressional Interest in Replimune Group, Inc. (REPL)
No congressional trades have been disclosed for Replimune Group, Inc. (REPL) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading REPL?
No congressional trades found for this stock.